Last reviewed · How we verify
ISIS apoC-III Rx
Antisense oligonucleotide that targets apolipoprotein C-III
Antisense oligonucleotide that targets apolipoprotein C-III Used for Hypertriglyceridemia.
At a glance
| Generic name | ISIS apoC-III Rx |
|---|---|
| Sponsor | Ionis Pharmaceuticals, Inc. |
| Drug class | Antisense oligonucleotide |
| Target | Apolipoprotein C-III |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
ISIS apoC-III Rx is an antisense oligonucleotide that specifically targets apolipoprotein C-III (apoC-III) for degradation, thereby reducing triglyceride levels.
Approved indications
- Hypertriglyceridemia
Common side effects
- Nausea
- Injection site reaction
- Fatigue
Key clinical trials
- Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISIS apoC-III Rx CI brief — competitive landscape report
- ISIS apoC-III Rx updates RSS · CI watch RSS
- Ionis Pharmaceuticals, Inc. portfolio CI